Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Abstract
Background The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF V600-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated effi cacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.
Domains
Cancer
Loading...